BIGBEAR
PHARMACEUTICAL
Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
AuthenticGuaranteeFast DeliveryPrivacy Enasidenib Pharmacokinetics1. Absorption: Absolute bioavailability is 57%, with a high-fat meal increasing exposure by 50%. Median time to peak concen···【More】
Update: 17 Jul,2026Source: BigbearViews: 104
Enasidenib, an antineoplastic agent, is a potent and selective inhibitor of isocitrate dehydrogenase-2 (IDH2), indicated for the treatment of relapsed···【More】
Update: 17 Jul,2026Source: BigbearViews: 97
Enasidenib may cause different side effects during treatment. If you do not have much knowledge about the side effects of enasidenib, it is recommende···【More】
Update: 17 Jul,2026Source: BigbearViews: 101
Enasidenib Dose Adjustments1. Hepatotoxicity ManagementBilirubin elevation (more than 3 times the upper limit of normal lasting for 2 weeks or longer,···【More】
Update: 17 Jul,2026Source: BigbearViews: 103
Enasidenib adult dosage is usually 100 mg once daily, and should be continued until disease progression or unacceptable toxicity occurs. For specific ···【More】
Update: 17 Jul,2026Source: BigbearViews: 103
Enasidenib is an oral targeted therapy used for acute myeloid leukemia (AML) that exerts its effects by blocking isocitrate dehydrogenase-2 (IDH2).Mec···【More】
Update: 09 May,2026Source: BigbearViews: 141
Enasidenib is an oral medication used to treat acute myeloid leukemia (AML) in adult patients. Acute myeloid leukemia (AML) is a type of cancer that a···【More】
Update: 09 May,2026Source: BigbearViews: 155
August 1, 2017 — The U.S. Food and Drug Administration (FDA) has approved Enasidenib for the treatment of adult patients with relapsed or refractory a···【More】
Update: 08 May,2026Source: BigbearViews: 156
On November 29, 2018, the U.S. Food and Drug Administration (FDA) issued a warning stating that signs and symptoms of a life-threatening side effect k···【More】
Update: 08 May,2026Source: BigbearViews: 150
Enasidenib dosage and administration must strictly follow the doctor's instructions and be administered under the guidance of a professional physi···【More】
Update: 24 Mar,2026Source: BigbearViews: 140
Enasidenib is the first FDA-approved treatment for acute myeloid leukemia (AML) targeting IDH2 mutations, indicated for relapsed or refractory adult p···【More】
Update: 18 Mar,2026Source: BigbearViews: 147
Precautions for EnxidipineEnxidipine is used for relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation. An FDA-approved diagnostic···【More】
Update: 18 Mar,2026Source: BigbearViews: 144
August 1, 2017 – The U.S. Food and Drug Administration (FDA) approved enasidenib for the treatment of adult patients with relapsed or refractory acute···【More】
Update: 10 Mar,2026Source: BigbearViews: 155
In addition to the expected therapeutic effects, some adverse reactions may occur when receiving enasidenib treatment. While not all side effects will···【More】
Update: 10 Mar,2026Source: BigbearViews: 138
On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 10 Mar,2026Source: BigbearViews: 133
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
